Literature DB >> 8304846

National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel.

.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8304846     DOI： 10.1001/archneur.1994.00540140115021

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  10 in total

1.  Type II neurofibromatosis presenting as quadriceps atrophy.

Authors:  L Grazzi; L Chiapparini; E A Parati; S Giombini; D D'Amico; M Leone; G Bussone
Journal:  Ital J Neurol Sci       Date:  1998-04

2.  Neurofibromatosis type 2 in an adolescent boy with polyneuropathy and a mutation in the NF2 gene.

Authors:  W C Overweg-Plandsoen; R Brouwer-Mladin; P Merel; L de Vries; E K Bijlsma
Journal:  J Neurol       Date:  1996-10       Impact factor: 4.849

Review 3.  Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes.

Authors:  Fausto J Rodriguez; Constantine A Stratakis; D Gareth Evans
Journal:  Acta Neuropathol       Date:  2011-12-31       Impact factor: 17.088

4.  Clinicopathologic assay of 15 tumor resections in a family with neurofibromatosis type 2.

Authors:  Salvatore Di Maio; Goran Mrak; Gordana Juric-Sekhar; Donald Born; Alessandra Mantovani; Laligam N Sekhar
Journal:  J Neurol Surg B Skull Base       Date:  2012-04

5.  The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.

Authors:  Mikkel Christian Alanin; Camilla Klausen; Per Caye-Thomasen; Carsten Thomsen; Kaare Fugleholm; Lars Poulsgaard; Ulrik Lassen; Morten Mau-Sorensen; Kenneth Francis Hofland
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-25       Impact factor: 2.503

6.  Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Authors:  Jaishri O Blakeley; Xiaobu Ye; Dan G Duda; Chris F Halpin; Amanda L Bergner; Alona Muzikansky; Vanessa L Merker; Elizabeth R Gerstner; Laura M Fayad; Shivani Ahlawat; Michael A Jacobs; Rakesh K Jain; Christopher Zalewski; Eva Dombi; Brigitte C Widemann; Scott R Plotkin
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

7.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

8.  Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2.

Authors:  Eiji Ito; Kiyoshi Saito; Hiroshi Yatsuya; Tetsuya Nagatani; Goro Otsuka
Journal:  Neurosurg Rev       Date:  2009-08-12       Impact factor: 3.042

9.  Family with neurofibromatosis type 2 and autosomal dominant hearing loss: identification of carriers of the mutated NF2 gene.

Authors:  E K Bijlsma; P Merel; P Fleury; C J van Asperen; A Westerveld; O Delattre; G Thomas; T J Hulsebos
Journal:  Hum Genet       Date:  1995-07       Impact factor: 4.132

Review 10.  Advances in the treatment of neurofibromatosis-associated tumours.

Authors:  Andrew L Lin; David H Gutmann
Journal:  Nat Rev Clin Oncol       Date:  2013-08-13       Impact factor: 66.675
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.